OTLK
Outlook Therapeutics Inc
$
2.130
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
2.240
Open
2.100
VWAP
2.15
Vol
1.65M
Mkt Cap
89.87M
Low
2.060
Amount
3.55M
EV/EBITDA(TTM)
--
Total Shares
23.41M
EV
113.67M
EV/OCF(TTM)
--
P/S(TTM)
--
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing ONS-5010/LYTENAVA (bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. It is advancing ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. ONS-5010/LYTENAVA, consisted of three clinical trials which it refers to as NORSE ONE, NORSE TWO and NORSE THREE.
Show More
1 Analyst Rating
275.59% Upside
Wall Street analysts forecast OTLK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OTLK is 8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
275.59% Upside
Current: 2.130
Low
8.00
Averages
8.00
High
8.00
275.59% Upside
Current: 2.130
Low
8.00
Averages
8.00
High
8.00
Guggenheim
Eddie Hickman
Buy
downgrade
$10 -> $8
2025-05-20
Reason
Guggenheim
Eddie Hickman
Price Target
$10 -> $8
2025-05-20
downgrade
Buy
Reason
Guggenheim analyst Eddie Hickman lowered the firm's price target on Outlook Therapeutics to $8 from $10 and keeps a Buy rating on the shares after having caught up with management following the company's Q2 earnings release. The cash position continues to be an overhang, but management is confident they have a runway to get to the Lytenava PDUFA date of August 27, the analyst tells investors.
Ascendiant Capital
Edward Woo
Strong Buy
Maintains
$33 → $24
2025-02-24
Reason
Ascendiant Capital
Edward Woo
Price Target
$33 → $24
2025-02-24
Maintains
Strong Buy
Reason
Chardan Capital
Daniil Gataulin
Hold
Maintains
$3
2025-02-18
Reason
Chardan Capital
Daniil Gataulin
Price Target
$3
2025-02-18
Maintains
Hold
Reason
HC Wainwright & Co.
Douglas Tsao
Strong Buy
Maintains
$30 → $3
2025-02-18
Reason
HC Wainwright & Co.
Douglas Tsao
Price Target
$30 → $3
2025-02-18
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Douglas Tsao
Strong Buy
Reiterates
$30
2025-01-17
Reason
HC Wainwright & Co.
Douglas Tsao
Price Target
$30
2025-01-17
Reiterates
Strong Buy
Reason
Guggenheim
Eddie Hickman
Strong Buy
Reiterates
$12
2025-01-17
Reason
Guggenheim
Eddie Hickman
Price Target
$12
2025-01-17
Reiterates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Outlook Therapeutics Inc (OTLK.O) is -1.60, compared to its 5-year average forward P/E of -4.30. For a more detailed relative valuation and DCF analysis to assess Outlook Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-4.30
Current PE
-1.60
Overvalued PE
-1.69
Undervalued PE
-6.90
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
311.77
Current PS
4.25
Overvalued PS
776.65
Undervalued PS
-153.12
Financials
Annual
Quarterly
FY2025Q2
N/A
Total Revenue
FY2025Q2
YoY :
-34.57%
-12.39M
Operating Profit
FY2025Q2
YoY :
-59.44%
-46.36M
Net Income after Tax
FY2025Q2
YoY :
-81.27%
-1.50
EPS - Diluted
FY2025Q2
N/A
Free Cash Flow
FY2025Q2
N/A
Gross Profit Margin - %
FY2025Q2
N/A
FCF Margin - %
FY2025Q2
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
1
28.4K
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
1
28.4K
USD
Months
OTLK News & Events
Events Timeline
2025-07-01 (ET)
2025-07-01
08:11:36
Outlook Therapeutics appoints Bob Jahr as CEO
2025-06-10 (ET)
2025-06-10
08:24:23
Outlook Therapeutics announces SMC recommendation of LYTENAVA
2025-06-02 (ET)
2025-06-02
07:06:17
Outlook Therapeutics announces commercial launch of LYTENAVA in Germany, UK
Sign Up For More Events
Sign Up For More Events
News
5.0
07-01NASDAQ.COMOutlook Therapeutics Appoints Bob Jahr As Chief Executive Officer
1.0
06-18NewsfilterOutlook Therapeutics to Participate in a Virtual Investor Lunch Break Event
9.0
06-10NewsfilterOutlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
Sign Up For More News
People Also Watch
PVL
Permianville Royalty Trust
1.860
USD
+0.54%
CGBS
Crown LNG Holdings Ltd
0
USD
-64.69%
SPRU
Spruce Power Holding Corp
1.420
USD
+2.90%
OVID
Ovid Therapeutics Inc
0.858
USD
+56.86%
ICAD
ICAD Inc
0
USD
+3.62%
FTCI
FTC Solar Inc
4.810
USD
0.00%
MAIA
Maia Biotechnology Inc
1.600
USD
+1.91%
GROV
Grove Collaborative Holdings Inc
1.470
USD
-0.68%
AP
Ampco-Pittsburgh Corp
3.210
USD
-5.59%
XLO
Xilio Therapeutics Inc
0.715
USD
+2.14%
FAQ
What is Outlook Therapeutics Inc (OTLK) stock price today?
The current price of OTLK is 2.13 USD — it has increased 1.91 % in the last trading day.
What is Outlook Therapeutics Inc (OTLK)'s business?
What is the price predicton of OTLK Stock?
What is Outlook Therapeutics Inc (OTLK)'s revenue for the last quarter?
What is Outlook Therapeutics Inc (OTLK)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Outlook Therapeutics Inc (OTLK)'s fundamentals?
How many employees does Outlook Therapeutics Inc (OTLK). have?